Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease

Thomas J Telfer; Jeffrey R Liddell; Clare Duncan; Anthony R White; Rachel Codd

Journal article

Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease

Thomas J Telfer, Jeffrey R Liddell, Clare Duncan, Anthony R White, Rachel Codd

Bioorganic & Medicinal Chemistry Letters | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2017

DOI: 10.1016/j.bmcl.2017.03.001

University of Melbourne Researchers

Jeffrey Liddell Author Pharmacology and Therapeutics

Anthony White Author Clinical Pathology

Related Projects (1)

Agents Targeting Iron In The Brain In Parkinson'S Disease

The impaired coordination and tremors experienced by the 64,000 Australians with Parkinson’s disease make managing life at work and home dif..

Grants

Awarded by NHMRC

Funding Acknowledgements

Funding from the NHMRC (APP1061761) is kindly acknowledged.

Citation metrics

6Web of Science

6Scopus

Keywords

Pharmacology & Pharmacy

Life Sciences & Biomedicine

Derivatives

Iron

Iron Chelators

Iron Chelating Agents

Polycyclic Cage Compounds

Hydrophobicity Parameters

Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease

University of Melbourne Researchers

Related Projects (1)

Agents Targeting Iron In The Brain In Parkinson'S Disease

Grants

Funding Acknowledgements

Citation metrics

Keywords

STUDY AT MELBOURNE

ABOUT US

CONTACT & MAPS

ALUMNI & FRIENDS

RESEARCH

ENGAGEMENT